The Effect of Oral Adenosine Triphosphate (ATP) Supplementation on Anaerobic Exercise in Healthy Resistance-Trained Individuals: A Systematic Review and Meta-Analysis.

Adenosine triphosphate (ATP) is an energy and signaling molecule. It is synthesized endogenously and can be taken as an oral supplement. This review aimed to identify the effects of oral ATP supplementation on anaerobic exercise in healthy resistance-trained adults. A systematic review and meta-analysis were performed based on the Preferred Reporting Items of Systematic Reviews and Meta-Analysis (PRISMA) criteria. The inclusion criteria were articles published from 2000 to 2022, with anaerobic variables (maximal strength, maximum repetitions, and maximum anaerobic power) measurable in healthy adults with experience in resistance training, only randomized placebo-controlled clinical trials (RCTs), and with the acute (a single dose 30 min to 24 h before the tests) and/or chronic (>1 day) oral supplementation of ATP. A total of five RCTs with 121 adult men were included. The oral ATP supplementation achieved significantly greater gains in maximal strength compared with the placebo (PL) (MD = 8.13 kg, 95%CI [3.36-12.90], p < 0.001). Still, no differences were observed in the maximum number of repetitions or the maximum anaerobic power. Furthermore, 400 mg of ATP showed improvement in anaerobic exercise regardless of the duration of the supplementation protocol. In conclusion, supplementation with 400 mg of ATP doses can improve maximal muscle strength in resistance-trained men.

Computed tomographic characterization of urinary stones in patients with urolithiasis from Southeast Mexico.

Urolithiasis (UL) is a severe public health concern in southeastern Mexico. Computed tomography (CT) is the first-line diagnostic method for patients with suspected UL. The present study aimed to characterize stones in the entire urinary system using CT and to contribute to personalized treatment in patients with UL. Patients >18 years of age with suspected UL were enrolled. Characteristics of UL included stone size, location (kidney, ureters, and bladder), composition of the stone in Hounsfield units (HU), presence of staghorn stone(s), and obstructive uropathy. Patients were stratified according to sex and age to determine whether stone size and HU were dependent on hormonal factors in females and on prostatic hyperplasia in males. The Mann-Whitney U test was used to compare median values. Frequencies are expressed as percentages and were analyzed using the Mantel-Haenszel chi-squared test. A total of 1150 patients were included in this study, of whom 744 (64.7 %) had UL in only 1 anatomical location in the urinary system, and 406 (35.3 %) had stones in ≥2 anatomical locations. Localization and stone size differed between males and females (p < 0.05). Additionally, males exhibited differences in HU (p = 0.024) and frequency of obstructive uropathy (p = 0.10) when stratified according to age (≤50 and > 50 years). In addition, females exhibited statistical differences in HU (p = 0.010) and kidney stone size (p = 0.047) dependent on age (≤47 and > 47 years). In conclusion, findings suggest that HU and stone size differ in different anatomical structures of the urinary system. In addition, differences in stone size and composition may be associated with age and sex.

Cystatin C is a marker for acute kidney injury, but not for mortality among COVID-19 patients in Mexico

ABSTRACT Background: Patients infected with SARS-CoV-2 can develop acute kidney injury (AKI), associated with adverse clinical outcomes. In Mexico, an AKI incidence of 60.7% was reported in patients with COVID-19. Serum cystatin C is a well-known marker for AKI. It has been postulated as a marker for mortality in Chinese patients with COVID-19. Information regarding levels of cystatin C in COVID-19-infected patients is nonexistent among Mexican or Latin American populations. Aim: This work aimed to assess the level of cystatin C as an indicator of AKI and mortality among COVID-19 patients from Mexico. Methods: A cross-sectional study among 38 adults was performed in the Regional High Specialty Hospital of the Yucatan Peninsula in Merida, Yucatan, Mexico. Baseline characteristics and clinical and biomechanical parameters were collected, and serum levels of cystatin C were measured by ELISA. Results: A total of 71% (27 patients) with COVID-19 developed AKI; 78% were men, and 22% were women. In addition, 60% of individuals (16 men; 7 women) died due to COVID-19 complications. Serum levels of cystatin C were higher in those individuals who developed AKI (p = 0.001). A logistic regression model indicated that individuals with serum levels of cystatin C above 0.84 ng/mL had a 23-fold increased risk of developing AKI (OR, 23.7, 95% CI, 2.59-217.00, p = 0.005). However, increased cystatin C was not independently associated with mortality in the Mexican population (HR, 1.01, 95% CI, 0.66-1.56, p = 0.959). Conclusion: The results suggest that serum levels of cystatin C indicate AKI in COVID-19 patients. Although we recommend caution when using serum cystatin C levels as an indicator of mortality among the Mexican population, it is essential to note that cystatin C elevates earlier than creatinine, which is an advantage for timely clinical interventions.

Esquema corto de Praziquantel para el tratamiento de la neurocisticercosis parenquimatosa / Short regimen of Praziquantel for the treatment of parenclymatose neurocysticercosis

Objetivo. La terapia para la neurocisticercosis parenquimatosa con praziquantel (PZQ) de 15 días ha mostrado ser efectiva. Las concentraciones en plasma y líquido cefalorraquídeo (LCR) del PZQ son más elevadas después de dos horas de su administración. Nosostros pensamos que el mantenimiento de concentraciones elevadas de PZQ por seis horas pudieran ser una terapia cisticida adecuada para estos pacientes. Métodos. Tratamos 30 pacientes con neurocisticercosis parenquimatosa con tres dosis orales de 25 mg por kg de peso de PZQ con intervalos de dos horas. Ellos recibieron dexametasona 10 mg intramuscular por tres días consecutivos a la administración del PZQ. Resultados. En 21 pacientes desaparecieron los quistes, en siete hubo una desaparición de 30 a 60 por ciento y dos pacientes permanecieron sin cambios. Del número total de quistes, hubo una tasa de desaparición de 70.7 por ciento. Dos pacientes presentaron crisis convulsivas, seis cefalea y otros más náusea. Ningún paciente cursó con convulsiones durante el tratamiento con antiepilépticos. Conclusión. El costo y el tiempo de administración del PZQ se reducen significativamente y la inflamación que sigue a la destrucción del parásito es tratada secuencialmente

Curvas de peso y talla según la edad en niños malnutridos fetales / Weight-height curves by age in fetal mal-nourished children

Se realizó un estudio transversal de crecimiento y desarrollo en 200 niños nacidos en el Hospital Ginecoobstétrico Docente "Mariana Grajales", de la Ciudad de Santa Clara, durante los años 1988 y 1989, 100 malnutridos fetales y 100 con crecimiento normal. El objetivo fundamental es valorar el ritmo de crecimiento y desarrollo somático (peso y talla) experimentando por éstos como resultado de la recuperación nutricional. Se obtuvo una diferenciación significativa de las variables peso y talla entre los grupos con los valores menores siempre en el grupo estudio, por lo que resulta claro que la recuperación nutricional posnatal no llegó a compensar el retardo producido por la malnutrición fetal, al menos en nuestra muestra. Confeccionamos gráficos de peso y talla para la edad y peso para la talla que pueden ser utilizados en otros estudios de niños cubanos

Curvas de peso y talla según la edad en niños malnutridos fetales / Weight-height curves by age in fetal mal-nourished children

Se realizó un estudio transversal de crecimiento y desarrollo en 200 niños nacidos en el Hospital Ginecoobstétrico Docente "Mariana Grajales", de la Ciudad de Santa Clara, durante los años 1988 y 1989, 100 malnutridos fetales y 100 con crecimiento normal. El objetivo fundamental es valorar el ritmo de crecimiento y desarrollo somático (peso y talla) experimentando por éstos como resultado de la recuperación nutricional. Se obtuvo una diferenciación significativa de las variables peso y talla entre los grupos con los valores menores siempre en el grupo estudio, por lo que resulta claro que la recuperación nutricional posnatal no llegó a compensar el retardo producido por la malnutrición fetal, al menos en nuestra muestra. Confeccionamos gráficos de peso y talla para la edad y peso para la talla que pueden ser utilizados en otros estudios de niños cubanos(AU)